Children in Belo Horizonte, Brazil, who lived in neighbourhoods where researchers released mosquitoes carrying the bacterium Wolbachia were far less likely to catch dengue or chikungunya than children in comparable neighbourhoods. The results of the EVITA dengue trial were presented on 21 November 2026 at the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in National Harbor, Maryland. The researchers reported an overall efficacy of 68.6% against infection with these viruses, according to a press release from Emory University, one of the institutions involved.

The finding matters because it comes from a randomised trial in a large city during an exceptional outbreak. Brazil's 2024 dengue epidemic was the largest in its recorded history, and the trial's follow-up period covered it.

How the trial worked

Wolbachia is a naturally occurring bacterium. When it is introduced into Aedes aegypti mosquitoes, it reduces their ability to transmit viruses such as dengue, Zika and chikungunya, and females pass it on to their offspring, so it can spread and settle in a local mosquito population. This is not genetic modification of the mosquitoes, although some Brazilian headlines described it that way.

The trial divided Belo Horizonte into 58 clusters built around schools. Researchers randomly assigned 29 clusters to receive releases of Wolbachia (wMel strain) mosquitoes on top of standard mosquito control, while the other 29 received standard control alone, meaning insecticide spraying and removal of breeding sites. Releases ran from January 2021 to May 2022. The team enrolled 5,757 schoolchildren aged six to 11, who gave a blood sample in 2020 and then once a year until 2024. Samples were tested for antibodies to the three viruses, which picks up infections whether or not a child felt ill.

According to ASTMH's account of the presentation, about 4% of tests were positive among children in the release areas, compared with 14% in the comparison areas. Efficacy was 68.5% against dengue and 73.3% against chikungunya. Luciano Moreira of Fiocruz and the World Mosquito Program in Brazil said the locally adapted mosquito strain had remained established for more than three years.

The study was led by researchers from the Federal University of Minas Gerais (UFMG), Fiocruz, the São José do Rio Preto medical school (FAMERP) and the World Mosquito Program in Brazil, together with Emory, Yale, Johns Hopkins and the University of Florida. It was funded by the US National Institutes of Health, which provided 83% of the money, and Brazil's Ministry of Health.

An outside specialist was enthusiastic. David Hamer, a global health expert at Boston University who was not involved in the study, called the result "really exciting" and said that wider use of Wolbachia mosquitoes alongside existing measures could bring dengue down to much lower levels in many places, according to a G1 report that follows the Associated Press coverage of the meeting.

Limits the researchers point out

These are conference results. The press release says the findings will be submitted to a peer-reviewed journal, so the full analysis has not yet been independently scrutinised. The World Mosquito Program, which develops and deploys the method, was one of the trial partners, which is worth keeping in mind even though the study was a randomised comparison run with several universities.

Zika cases were too few for the team to say whether the mosquitoes had any effect on that virus, G1 reported. Albert Ko of Yale, a co-principal investigator, told the meeting that Wolbachia "is not going to be a magic bullet": it reduces infections but does not eliminate them, so outbreaks remain possible. He also raised the question of fair access, noting that Singapore plans to invest heavily in the approach while many poorer places cannot. FAMERP virologist Maurício Nogueira said he expects viruses to develop some resistance "at some point", though the biology involved may make that harder.

The result adds to an earlier trial in Yogyakarta, Indonesia, which measured symptomatic dengue. Ko said the two together could support a case for WHO prequalification and wider use, but no such decision has been made.